Jinglong Chen

No ORCID on file · 1 paper in corpus

2018

IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway.

Cancer cell international ·doi:10.1186/s12935-018-0671-3

BackgroundSorafenib is the standard targeted drug used to treat hepatocellular carcinoma (HCC), but the therapeutic response between individuals varies markedly. Recently, cytokine-based immunotherapy has been a topic of intense discussion …